RGH 363

Drug Profile

RGH 363

Alternative Names: RGH-363

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gedeon Richter
  • Class Antipsychotics
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Schizophrenia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Schizophrenia in United Kingdom
  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
  • 26 Jul 2010 RGH 363 is still in phase I trials for Schizophrenia in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top